Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed May 5, 2015
Insider Transaction Report
Form 4
Stolz Brian M.
EVP, Administration and CHCO
Transactions
- Exercise/Conversion
Common Stock, no par value
2015-05-01+3,675→ 96,060 total - Exercise/Conversion
Restricted Share Units
2015-05-01−3,675→ 0 total→ Common Stock (3,675 underlying) - Tax Payment
Common Stock, no par value
2015-05-01−1,921→ 94,139 total
Footnotes (3)
- [F1]Each performance-based Restricted Share Unit ("PSU") represents a contingent right to receive between zero and three common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"), subject to performance based vesting criteria. See note (2).
- [F2]This represents the number of units vested on the PSUs that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return ("TSR") between a price of $43.50 starting on December 7, 2011 and the average stock price for the 20 trading days starting on each measurement dates: 25% on September 7, 2014, 50% on December 7, 2014 and 25% on March 7, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. These performance-based RSUs have now vested in full.
- [F3]This number represents common shares withheld to satisfy the tax withholding obligations due upon vesting of performance-based RSUs.